Pricing Log in Create free account

Liminatus Pharma Inc. (LIMN) vs Panbela Therapeutics Inc. (PBLA)

Liminatus Pharma Inc. and Panbela Therapeutics Inc. are both Biotechnology companies. Liminatus Pharma Inc. and Panbela Therapeutics Inc. are of similar size ($3.5M and $3.4M). Across the 8 metrics below, Liminatus Pharma Inc. leads on 5 and Panbela Therapeutics Inc. on 3.

Valuation

Metric LIMN PBLA Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 8.05 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (940.00%) (322,700.00%) (32.88%)
Free cash flow yield (164.16%) (29,656.02%) (23.13%)

Profitability

Metric LIMN PBLA Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 294.43% 270.37% (51.96%)
Return on assets (471.47%) (353.47%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric LIMN PBLA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (112.19%) 99.43% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LIMN PBLA Biotechnology median
Debt to equity 4.80 (0.23) 0.00
Current ratio 1.12 0.26 4.97
Net debt to EBITDA (0.37) (0.10) 1.01

Dividend

Metric LIMN PBLA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LIMN PBLA Biotechnology median
Market cap 3.53m 3.35m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack